Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 5.4% – What’s Next?

Posted by George Bondi on Jul 15th, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report)’s share price traded down 5.4% during mid-day trading on Wednesday . The company traded as low as $35.52 and last traded at $35.8810. Approximately 13,574 shares traded hands during trading, a decline of 95% from the average session volume of 291,457 shares. The stock had previously closed at $37.91.

Analyst Ratings Changes

A number of research firms have commented on MPLT. Benchmark reiterated a “buy” rating on shares of Maplight Therapeutics in a report on Monday, June 22nd. Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 price objective on the stock. UBS Group began coverage on Maplight Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $48.00 target price for the company. Stifel Nicolaus upped their price objective on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maplight Therapeutics in a research report on Monday. Five analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $39.10.

Check Out Our Latest Stock Report on MPLT

Maplight Therapeutics Price Performance

The company’s 50 day simple moving average is $31.00 and its 200 day simple moving average is $24.01. The firm has a market cap of $1.56 billion and a price-to-earnings ratio of -0.89.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, analysts forecast that Maplight Therapeutics, Inc. will post -5.13 earnings per share for the current year.

Insider Transactions at Maplight Therapeutics

In other Maplight Therapeutics news, CEO Christopher A. Kroeger sold 118,235 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $27.19, for a total value of $3,214,809.65. Following the completion of the sale, the chief executive officer owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. The trade was a 7.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Erin Pennock Foff sold 4,438 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $28.54, for a total transaction of $126,660.52. Following the sale, the insider owned 346,059 shares of the company’s stock, valued at approximately $9,876,523.86. This represents a 1.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 495,244 shares of company stock valued at $14,079,461 over the last quarter. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Maplight Therapeutics

Several hedge funds have recently modified their holdings of the business. Strs Ohio acquired a new stake in shares of Maplight Therapeutics during the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Maplight Therapeutics in the 4th quarter valued at approximately $70,000. New York State Common Retirement Fund acquired a new position in Maplight Therapeutics during the fourth quarter worth $93,000. MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics during the fourth quarter worth $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics in the fourth quarter valued at $205,000.

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.